122 related articles for article (PubMed ID: 20153025)
1. Influence of anticoagulant therapy with vitamin K antagonists on plasma levels of coagulation factor VIII.
Passamonti SM; Bucciarelli P; Bader R; Martinelli I
Thromb Res; 2010 Sep; 126(3):243-5. PubMed ID: 20153025
[TBL] [Abstract][Full Text] [Related]
2. 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII.
Eischer L; Gartner V; Schulman S; Kyrle PA; Eichinger S;
Ann Hematol; 2009 May; 88(5):485-90. PubMed ID: 18931845
[TBL] [Abstract][Full Text] [Related]
3. D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis.
Cosmi B; Legnani C; Cini M; Favaretto E; Palareti G
Thromb Res; 2008; 122(5):610-7. PubMed ID: 18304616
[TBL] [Abstract][Full Text] [Related]
4. D-Dimer Levels and Vitamin K Antagonist Therapy in Deep Vein Thrombosis of the Legs.
Park JK; Koo do H; Yoon DH; Lee JN
Ann Vasc Surg; 2016 Jul; 34():119-34. PubMed ID: 27177705
[TBL] [Abstract][Full Text] [Related]
5. Risk factors of vitamin K antagonist overcoagulation. A case-control study in unselected patients referred to an emergency department.
Cadiou G; Varin R; Levesque H; Grassi V; Benichou J; Tiret I; Dieu B; Lecam-Duchez V; Borg JY; Muller JM; Benhamou Y; Marie I
Thromb Haemost; 2008 Oct; 100(4):685-92. PubMed ID: 18841293
[TBL] [Abstract][Full Text] [Related]
6. Decreased procoagulant phospholipids in patients treated by vitamin K antagonists.
Rousseau A; Woodhams B; Paunet-Bobo M; Van Dreden P; Bigot D; Leclerc S; Lenormand B; Vasse M
Thromb Res; 2012 Sep; 130(3):491-4. PubMed ID: 22551976
[TBL] [Abstract][Full Text] [Related]
7. Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate.
Majeed A; Meijer K; Larrazabal R; Arnberg F; Luijckx GJ; Roberts RS; Schulman S
Thromb Haemost; 2014 Feb; 111(2):233-9. PubMed ID: 24154891
[TBL] [Abstract][Full Text] [Related]
8. Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin.
Gerotziafas GT; Dupont C; Spyropoulos AC; Hatmi M; Samama MM; Kiskinis D; Elalamy I
Thromb Haemost; 2009 Jul; 102(1):42-8. PubMed ID: 19572066
[TBL] [Abstract][Full Text] [Related]
9. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
[TBL] [Abstract][Full Text] [Related]
10. How should we determine length of anticoagulation after proximal deep vein thrombosis of the lower limbs?
Siragusa S; Caramazza D; Malato A
Br J Haematol; 2009 Mar; 144(6):832-7. PubMed ID: 19183183
[TBL] [Abstract][Full Text] [Related]
11. Is early antithrombotic therapy necessary after tissue mitral valve replacement?
Colli A; D'Amico R; Mestres CA; Pomar JL; Cámara ML; Ruyra X; Mulet J
J Heart Valve Dis; 2010 Jul; 19(4):405-11. PubMed ID: 20845885
[TBL] [Abstract][Full Text] [Related]
12. Risk factors of vitamin K antagonist overcoagulation.
Marie I; Leprince P; Menard JF; Tharasse C; Levesque H
QJM; 2012 Jan; 105(1):53-62. PubMed ID: 21880698
[TBL] [Abstract][Full Text] [Related]
13. Abrupt versus gradual withdrawal of vitamin K antagonist treatment in patients with venous thromboembolic disease: assessment of hypercoagulability and clinical outcome.
de Groot MR; Njo TL; van Marwijk Kooy M; Büller HR
Clin Lab; 2000; 46(11-12):575-81. PubMed ID: 11109505
[TBL] [Abstract][Full Text] [Related]
14. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy.
Zolfaghari S; Harenberg J; Froelich L; Wehling M; Weiss C
Semin Thromb Hemost; 2014 Feb; 40(1):121-8. PubMed ID: 24381153
[TBL] [Abstract][Full Text] [Related]
15. Temporal trends in the prescription of vitamin K antagonists in patients with atrial fibrillation.
Friberg J; Gislason GH; Gadsbøll N; Rasmussen JN; Rasmussen S; Abildstrøm SZ; Køber L; Madsen M; Torp-Pedersen C
J Intern Med; 2006 Feb; 259(2):173-8. PubMed ID: 16420546
[TBL] [Abstract][Full Text] [Related]
16. D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis.
Cosmi B; Legnani C; Cini M; Guazzaloca G; Palareti G
Thromb Haemost; 2005 Nov; 94(5):969-74. PubMed ID: 16363238
[TBL] [Abstract][Full Text] [Related]
17. The acute phase reaction explains only a part of initially elevated factor VIII:C levels: a prospective cohort study in patients with venous thrombosis.
Tichelaar V; Mulder A; Kluin-Nelemans H; Meijer K
Thromb Res; 2012 Feb; 129(2):183-6. PubMed ID: 21992898
[TBL] [Abstract][Full Text] [Related]
18. [Influence of oral anticoagulant treatment on D-dimers levels].
Ombandza-Moussa E; Samama MM; Horellou MH; Chatelier AL; Elalamy I; Conard J
Ann Biol Clin (Paris); 2001; 59(5):579-83. PubMed ID: 11602388
[TBL] [Abstract][Full Text] [Related]
19. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism.
Veeger NJ; Piersma-Wichers M; Tijssen JG; Hillege HL; van der Meer J
Br J Haematol; 2005 Feb; 128(4):513-9. PubMed ID: 15686461
[TBL] [Abstract][Full Text] [Related]
20. Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists.
Tripodi A; Primignani M; Braham S; Chantarangkul V; Clerici M; Moia M; Peyvandi F
Dig Liver Dis; 2016 Oct; 48(10):1208-13. PubMed ID: 27470055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
